Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Open-label Study of Dapagliflozin in Japanese Subjects With Type 2 Diabetes Mellitus
jRCT2080221436Phase 3
- Sponsor
- AstraZeneca
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080221436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221436.